Drug profile · INN
ramucirumab
CYRAMZA
ramucirumab (CYRAMZA) is a vascular endothelial growth factor receptor 2 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — ramucirumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 14
- Data quality
- 0.84
Quick answer
ramucirumab (CYRAMZA) is a vascular endothelial growth factor receptor 2 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor receptor 2 inhibitor
Primary target: Vascular endothelial growth factor receptor 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ramucirumab?
ramucirumab (CYRAMZA) is a vascular endothelial growth factor receptor 2 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ramucirumab?
CYRAMZA is a marketed brand name for ramucirumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ramucirumab?
ramucirumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.